Stargardt Disease Market Size is expected to grow at a moderate rate, owing to the rise in geriatric population along with the emerging therapies by major companies

Stargardt Disease Market

DelveInsight’s Stargardt Disease market report provides a comprehensive understanding of Stargardt Disease, historical and forecasted epidemiology, and Stargardt Disease market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). The report also examines current Stargardt Disease treatment practices/algorithms, Stargardt Disease market drivers, Stargardt Disease market barriers, and unmet medical needs to identify and evaluate the market’s underlying potential.

Key Highlights from the Stargardt Disease Market Report

• The National Institute for Health estimates that 1 in 8,000 to 10,000 people have Stargardt Disease.

• According to the American Institute of Ophthalmology, Stargardt Disease is the most commonly inherited childhood and adult maculopathy. 

• The major pharmaceutical companies involved in the Stargardt Disease market include Acucela Inc. (now Kubota), Astellas Pharma, Alkeus Pharmaceuticals, ProQR, Revision Therapeutics, and others.

• The stem cell treatment ASP7317 developed by Astellas is intended to protect and regenerate photoreceptors in the retina that have been damaged by eye diseases such as Stargardt’s. It is currently in Phase II of Stargardt Disease clinical trials.

• REV-0100 by Revision Therapeutics is a repurposed, GRAS compound in pre-clinical development for Stargardt Disease treatment as a first-line therapy or in combination. The US Food and Drug Administration has awarded it both orphan drug designation as well as rare pediatric disease designation.

• The European Medicines Agency (EMA) recently granted orphan designation to Acucela Inc.’s (now Kubota) leading drug candidate Emixustat hydrochloride for Stargardt Disease treatment.

• QR-1011 is being developed by ProQR to treat Stargardt Disease caused by the c.5461-10T>C mutation in ABCA4.

For more information on treatment for stargardt disease, request sample @ Stargardt Disease Treatment Market

The Stargardt Disease market report also covers current treatment practices, developing drugs, individual Stargardt Disease therapy market shares, and current and predicted Stargardt Disease market sizes from 2018 to 2030, segmented by seven major markets.

Stargardt Disease: Overview

Stargardt Disease (STGD) is named after Karl Stargardt, a German ophthalmologist who first reported a case in his practice in 1901. Stargardt Disease is the most common inherited single-gene retinal disease. It is usually inherited in an autosomal recessive manner due to mutations in the ABCA4 gene. It is rarely inherited autosomally dominantly due to ELOVL4 or PROM1 gene defects. It is distinguished by macular degeneration that begins in childhood, adolescence, or adulthood and results in progressive vision loss.

Stargardt Disease Epidemiology Segmentation

The Stargardt Disease report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Stargardt Disease Total Prevalent Cases

• Stargardt Disease Diagnosed and Treatable Cases 

• Stargardt Disease Type-Specific Cases

• Stargardt Disease Gender-Specific Cases

• Stargardt Disease Age-Specific Cases

Stargardt Disease Treatment Landscape

Stargardt Disease, like other types of macular degeneration, currently has no cure. If there is blood vessel proliferation or leakage, it is sometimes treated with intraocular injections of anti-VEGF drugs, similar to “wet” Age-related Macular Degeneration treatments.

Get a complete understanding of stargardt disease gene therapy @ Stargardt Disease Clinical Trials

Stargardt Disease Market

The dynamics of the Stargardt Disease market are expected to change in the upcoming years due to new treatment options and an increase in healthcare spending around the world. Key companies such as Acucela Inc (Kubota), Alkeus Pharmaceuticals Inc, Astellas Pharma Inc, Revision Therapeutics, and others are developing several promising drug candidates for Stargardt Disease treatment.

Stargardt Disease Pipeline Therapies and Key Companies

• Emixustat: Acucela Inc.

• ASP7317: Astellas Pharma

• ALK-001: Alkeus Pharmaceuticals

• QR-1011: ProQR

• REV-0100: Revision Therapeutics

Stargardt Disease Market Drivers

• Emerging Pipeline

• Increasing Number of Cases

• Technological Advancements

Stargardt Disease Market Barriers

• No Treatment

• Lack of Data

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2018-30

Stargardt Disease Key Companies: Acucela Inc., Astellas Pharma, Alkeus Pharmaceuticals, ProQR, Revision Therapeutics, among others. 

Stargardt Disease Key Pipeline Therapies: Emixustat, ASP7317, ALK-001. QR-1011, REV-0100,and others.

Stargardt Disease Segmentation: By Geography, By Stargardt Disease therapies

Analysis: Comparative and conjoint analysis of Stargardt Disease emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Wet Macular Degeneration Market

Get comprehensive historical and forecast analysis of Wet Macular Degeneration Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Novartis, Pfizer, Roche, Hemera Biosciences, Ribomic USA Inc, PanOptica, Inc., Alkahest Inc, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/